Author

admin

Browsing

  • MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.

  • New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.

  • Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions advancing with leading pharmaceutical companies.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the successful completion of a private placement offering (the ‘Offering’) of units (‘Units’) for net proceeds of US$11 million. The initial closing of US$10 million has been completed, with the remaining US$1 million to close on Monday, October 20, 2025.

‘As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with several prominent centers across the U.S. now enrolling patients, we are pleased to have secured a direct investment of US$11 million to strengthen our balance sheet and accelerate the development of our novel heart failure drug, CRD-38, based on the recently reported findings from our ARCHER trial,’ said David Elsley, President and CEO of Cardiol Therapeutics. ‘Topline results from our ARCHER trial demonstrated a significant reduction in LV mass-marking the first evidence of structural and remodeling improvement in patients with myocarditis. This landmark finding represents our second clinical validation in inflammatory heart disease and establishes a key translational link to data published earlier this year in the Journal of the American College of Cardiology, which demonstrated the beneficial effects of the active pharmaceutical ingredient or API in CardiolRx on cardiac structure, inflammation, and fibrosis in a model of heart failure. The ARCHER findings support pursuing an additional Orphan Drug Designation for CardiolRx in myocarditis and advancing the development of our next-generation CRD-38 formulation, which delivers the same API via subcutaneous administration, to target the broader heart failure market. Notably, blockbuster drugs that reduce LV mass have been shown to lower heart failure-related death and hospitalization, underscoring the clinical potential of Cardiol’s differentiated anti-inflammatory mechanism to address a large unmet need in heart failure, where five-year mortality rates still exceed 50%.’

Under the Offering, the Company sold a total of 11 million Units at a price of US$1.00 per Unit. Each Unit consists of one Class A common share of the Company (a ‘Common Share‘) and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one additional Common Share at an exercise price of US$1.35 for a period of 24 months from the date of issuance. The warrants include an acceleration provision, allowing the Company to advance their expiry to the 30th day following the issuance of a news release if the daily volume-weighted average trading price of the Common Shares exceeds US$2.00 for five consecutive trading days. Proceeds from the Offering provide cash resources that are anticipated to support operations into the third quarter of 2027.

The securities have not been registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any U.S. state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the ‘United States’ or ‘U.S. persons’ (as such terms are used in Regulation S under the U.S. Securities Act), absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with an exemption therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Certain insiders of the Company participated in the Offering. Such participation is considered to be a ‘related-party transaction’ within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related-party participation in the Offering as the fair market value (as determined under MI 61-101) of the subject matter of, and the fair market value of the consideration for, the transaction, insofar as it involved interested parties, did not exceed 25% of the Company’s market capitalization (as determined under MI 61-101).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

The ARCHER Program (NCT05180240) comprises the completed Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward-looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for use in heart failure, the Company’s presentation and publication of the comprehensive ARCHER trial data, the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis, and statements regarding the expected length and scope of funding for the Company’s development plans as a result of the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270946

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

Americans have delivered the same message in the last two elections: make life affordable again. 

They are tired of working harder for less, while the cost of everything — from housing to education to insurance — keeps rising. The affordability crisis touches every household, and its biggest driver is the one Washington refuses to tackle seriously: healthcare. 

Healthcare now consumes nearly one-fifth of our economy. It is the largest single cost for employers, the fastest-growing burden on families, and the quietest drain on national growth. Every dollar businesses spend on bloated health costs is a dollar not available for higher wages, new jobs or investment. Every dollar families spend on premiums or out-of-pocket costs is a dollar they can’t use for savings, housing or opportunity. Until we fix healthcare, we can’t fix affordability. 

It’s not that Washington ignores healthcare — it’s that it thinks about it too narrowly. Politicians obsess over temporary subsidies, tax credits and program expansions that make insurance more expensive to subsidize but never make care itself more affordable. The current fight over extending COVID-era insurance subsidies is a perfect example. Even supporters of Obamacare now admit that the ‘Affordable’ Care Act turned out to be unaffordable. Their answer is to borrow more money to prop up a system that keeps getting worse. That is not reform — it’s surrender.

There are three truths both parties must face. 

First, the system is already too expensive and locked in a pattern that guarantees it will grow more unaffordable every year. 

Second, 60 years of bureaucratic control — public and private — have utterly failed to contain costs.

Third, we must build a new model that relies on patients, doctors and employers — not massive government and insurance-company bureaucracies — to achieve the change Americans want. 

That model is not theoretical — it already works in the rest of our economy. When people have access to clear prices and quality information before making decisions, competition drives innovation, choice and lower costs. Technology has made this possible in every industry, from travel to retail to manufacturing. If the same principles applied to healthcare, we could unleash that same power to lower costs and improve quality. 

Instead, our opaque, bureaucratic system hides prices and multiplies middlemen. The average family of four now spends roughly $27,000 a year on health insurance — about the cost of a new Chevrolet or Toyota every 12 months. Most families don’t see the full bill because their employer or the government pays much of it, but that just means their wages are smaller. Paying the equivalent of a new car every year just for coverage is why Americans list affordability as their top economic concern.

Worse, nobody knows what anything costs — not patients, not families, not even the self-funded employers who pay the claims for their plan members. Bills arrive months after care, after passing through a maze of third-party administrators, repricers and billing vendors. That secrecy fuels waste, fraud and frustration. It’s estimated that 30% to 50% of all healthcare spending is administrative rather than medical. In short, America’s healthcare system has more middlemen than medicine. 

And who benefits? Powerful interest groups, insurers, consultants and bureaucracies that profit from complexity and confusion. As Tom Cruise shouted in ‘Jerry Maguire’: ‘Show me the money.’ Behind the speeches and lobbyists defending this broken system are people determined to protect their share of a bankrupting status quo. 

Second, 60 years of bureaucratic control — public and private — have utterly failed to contain costs.

Politicians can’t fight every entrenched interest group — but millions of patients and doctors armed with real price and quality information can. Transparency gives power back to those who actually deliver and receive care. When they can see what things cost, they can make smarter choices, reward efficiency and hold wasteful players accountable. Transparency doesn’t just lower prices — it changes who holds the power.

That’s why President Donald Trump’s price-transparency executive order in his first administration was a genuine breakthrough. It required hospitals and insurers to publish negotiated prices and, through the No Surprises Act, directed officials to create Advance Explanations of Benefits (AEOBs) so Americans could know their costs before receiving care. Trump started the transparency revolution. Under the Biden administration, enforcement stalled, and patients never saw the full benefit. 

Now Trump has the chance to finish what he began — and make transparency permanent. 

The administration has the authority to act right now under his ‘radical transparency’ executive order issued earlier this year, the No Surprises Act, and existing Employee Retirement Income Security Act authority. The Centers for Medicare & Medicaid Services should immediately issue and enforce AEOB rules. The Department of Labor should guarantee employers access to complete claims and pricing data while protecting patient privacy. If the administration moves quickly, Americans could begin receiving AEOBs in 2026 — and Trump could rightfully claim a historic victory for transparency, competition and higher wages before the midterms. 

Congress should reinforce this effort by passing the bipartisan Patients Deserve Price Tags Act, led by Kansas Republican Sen. Roger Marshall and Colorado Democrat Sen. John Hickenlooper. The bill secures employer access to data and ensures no third-party administrator can hide prices from the people who pay the bills. The executive branch can act today; Congress should make it permanent.

When every patient and employer can see prices, markets will clean out waste on their own. Transparency gives employers the power to negotiate directly with providers and patients the ability to choose wisely. Prices in the open create competition that middlemen can’t survive and costs they can’t hide. The ripple effect — lower costs, higher wages, more investment — will strengthen every part of the economy. 

If America truly wants to make life affordable again, healthcare transparency is where we start.

It’s bold. It’s achievable. And it’s the single biggest step we can take to restore prosperity for working families.   

Disclaimer: Gingrich 360 has consulting clients in the healthcare industry which may be impacted by changes to healthcare laws. 

This post appeared first on FOX NEWS

The Department of Homeland Security (DHS) provided an update Sunday morning, saying TSA PreCheck is operating normally Sunday following reports that it had been suspended amid the partial government shutdown.

The suspension of the TSA PreCheck and Global Entry programs was first reported by The Washington Post, which noted the changes would begin Sunday at 6 a.m. EST. DHS says it will now be evaluating PreCheck on a ‘case by case basis.’

‘At this time, TSA PreCheck remains operational with no change for the traveling public. As staffing constraints arise, TSA will evaluate on a case by case basis and adjust operations accordingly,’ TSA wrote in a statement on X.

‘Courtesy escorts, such as those for Members of Congress, have been suspended to allow officers to focus on the mission of securing America’s skies,’ it added.

Homeland Security Secretary Kristi Noem on Saturday blamed Democrats for shutting down the government, saying they were causing ‘serious real world consequences.’

‘This is the third time that Democrat politicians have shut down this department during the 119th Congress,’ Noem said in a statement provided to Fox News Digital. ‘Shutdowns have serious real world consequences, not just for the men and women of DHS and their families who go without a paycheck, but it endangers our national security.’

Noem said the department was making ‘tough but necessary workforce and resource decisions to mitigate the damage inflicted by these politicians.’

She said TSA and U.S. Customs and Border Protection (CBP) would be ‘prioritizing the general traveling population at our airports and ports of entry and suspending courtesy and special privilege escorts.’ The Federal Emergency Management Agency (FEMA), she added, will halt all non-disaster-related response to prioritize disasters.

Noem noted the suspension comes as a major storm is expected to hit the Mid-Atlantic and Northeast.

Rep. Bennie Thompson, D-Miss., ranking member of the House Homeland Security Committee, criticized the Trump administration for ‘idiotically’ shutting down the programs ‘to punish the American people.’

‘This is Trump and Kristi Noem purposely punishing the American people and using them as pawns for their sadistic political games,’ he said in a statement. ‘TSA PreCheck and Global Entry REDUCE airport lines and ease the burden on DHS staff who are working without pay because of Trump’s abuse of the Department and killing of American citizens.’

He called on the administration to immediately reverse the decision.

The third government shutdown in under half a year began on Feb. 14 after Democrats and Republicans were at an impasse on reaching a deal regarding President Donald Trump’s immigration crackdown.

DHS was the only department left without federal funding after Democrats walked away from a bipartisan plan released last month in response to the deaths of two U.S. citizens at the hands of federal law enforcement agents in Minneapolis during anti-ICE demonstrations.

DHS is the third-largest Cabinet agency with nearly 272,000 employees. Roughly 90% of DHS workers were expected to continue working, many without pay, according to the department’s Sept. 2025 government shutdown plan.

DHS has jurisdiction over numerous agencies and offices, including CBP, TSA, FEMA, Immigration and Customs Enforcement (ICE), the U.S. Coast Guard, and the U.S. Secret Service.

Fox News Digital’s Elizabeth Elkind and Alex Miller contributed to this report.

This post appeared first on FOX NEWS

The Government of Ontario started taking applications for resource development projects under its “One Project, One Process” framework on Friday (October 17).

The new process, which Ontario lawmakers introduced in the spring, promises to streamline and reduce the permitting time for selected projects by at least half, introducing a dedicated office to consolidate applications. Under the current system, the permitting process can add up to 15 years to a project’s development cycle, the government stated.

In addition to supporting Ontario’s mining industry, the new framework is also a reaction to policy shifts in the United States under the Trump administration, as his tariff policy affects the Ontario and Canadian economies.

“With President Trump taking direct aim at our economy, it has never been more important to protect Ontario jobs and build the mines that will power our future,” said Stephen Lecce, Minister of Energy and Mines.

The new policy is similar to the national one introduced by Prime Minister Mark Carney in September. That program, which created the Major Projects Office, is geared to support investment and permitting for projects deemed to be in the national interest. The initiative was part of his election platform earlier in the year in response to Trump’s tariffs on imports of Canadian goods.

In a speech to the Peterson Institute of International Economics on Thursday (October 16), Bank of Canada Governor Tiff Macklem stated that Canada’s growth outlook remains “soft.”

He identified several trends that are affecting Canadian and global economies. The first is a slowing of global trade that began in 2010, which then accelerated as Trump increased tariff rates to the highest levels since the 1930s.

The second is a shift away from the US as the world’s largest trading hub, as supply chains strengthen in China and Europe, creating new hubs there. Macklem also noted that, while the US remains dominant in global finance, investors have expressed uncertainty due to its declining trade position and increasing debt load.

For Canada, Macklem said the tariffs have affected cross-border trade and stymied investment into Canadian industries, weakening gross domestic product growth.

Although it’s uncertain if the Bank of Canada will cut its rate when it makes its next policy decision on October 29, Macklem said, “Monetary policy cannot undo the damage of tariffs.” Instead, he suggested that Canada needs to lower barriers to interprovincial trade and focus on projects that increase the export of Canadian goods overseas.

South of the border, Federal Reserve Chairman Jerome Powell gave a speech on Tuesday (October 14) to the National Association of Business Economics in Philadelphia. In his remarks, he said the outlook for the jobs market and inflation has not changed since September, and signaled the likelihood of another rate cut when the Federal Open Market Committee meets on October 28 and 29.

In the days following Powell’s remarks, the price of gold surged to a new record high of US$4,379.13 on Thursday, and silver rose to a new record of US$54.40 per ounce. Both have since retreated, but remain elevated.

For more on what’s moving markets this week, check out our top market news round-up.

Markets and commodities react

Canadian equity markets were down this week.

The S&P/TSX Composite Index (INDEXTSI:OSPTX) lost 0.71 percent over the week to close Friday at 30,108.48.

The S&P/TSX Venture Composite Index (INDEXTSI:JX) fared worse, ending the week down 3.85 percent at 965.58. The CSE Composite Index (CSE:CSECOMP) also fell this week, shedding 5.33 percent to close out the week at 179.76.

The gold price set another new record, reaching an intraday high of US$4,379.13 per ounce in early morning trading Friday EST before retreating to US$4,252.69 by Friday’s close. Ultimately, gold was up 5.82 percent over the week.

The silver price also gained significantly this week, again breaking its own all-time high in early trading Friday when it reached US$54.47 per ounce. However, it had pulled back US$51.76 by 4:00 p.m. EDT Friday, posting a weekly gain of 3.46 percent.

The copper price was flat on the week, down just 0.2 percent to US$5.03 per pound.

The S&P Goldman Sachs Commodities Index (INDEXSP:SPGSCI) fell 2.23 percent to end Friday at 539.84.

Top Canadian mining stocks this week

How did mining stocks perform against this backdrop?

Take a look at this week’s five best-performing Canadian mining stocks below.

Stocks data for this article was retrieved at 4:00 p.m. EDT on Friday using TradingView’s stock screener. Only companies trading on the TSX, TSXV and CSE with market caps greater than C$10 million are included. Mineral companies within the non-energy minerals, energy minerals, process industry and producer manufacturing sectors were considered.

1. JZR Gold (TSXV:JZR)

Weekly gain: 112.77 percent
Market cap: C$28.95 million
Share price: C$0.50

JZR Gold is a gold company with exposure to the Vila Nova gold project, located in Amapá, Brazil, through a joint venture royalty agreement with the project’s operator, ECO Mining Oil & Gaz Drilling and Exploration.

JZR received a 50 percent net profit interest in the Vila Nova project following the completion of payments totaling US$6 million to ECO in January 2023. The funds were used to advance the project and construct an 800 metric ton per day bulk sampling gravimetric mill at the site.

According to JZR, the funding is considered a loan and will be “repaid to the Company from the proceeds of the sale of any products, prior to the distribution of any profits.”

The project holds approximately 9 million metric tons of gold tailings grading an average of 2.47 grams per metric ton (g/t) gold from historic operations. The companies plan to reprocess the tailings to generate near-term cash flow that will fund further exploration at the site, anticipating production of 2 kilograms of gold per day.

Shares gained this week alongside the October 14 news that ECO produced the first gold concentrate from the Vila Nova gold project’s mill. JZR said that ECO has begun to stockpile material at the mill site as it continues testing and optimization, with the goal of improving efficiency and increasing throughput.

2. Austral Gold (TSXV:AGLD)

Weekly gain: 90 percent
Market cap: C$75.37 million
Share price: C$0.095

Austral Gold is a gold production company operating two mines in Latin America.

Its Guanaco – Amancaya mine complex in Chile is its primary operation, hosting a 1,500 metric ton per day milling circuit, a 3,000 metric ton per day crushing circuit and a heap leaching processing plant. In 2024, the complex produced 15,138 ounces of gold and 37,154 ounces of silver.

Austral’s other operation is the Casposo – Manantiales complex in Argentina, which hosts a 1,100 metric ton per day mill and a dry-stack tailings facility. The mine had been on care and maintenance since 2019, during which time Austral worked on exploration at the site, along with its refurbishment plan to restart operations.

Shares in Austral rose this week following a pair of announcements on Tuesday.

The first was a report that Austral has resumed production at Casposo, currently sourcing material from the existing stockpiles. The company said it plans to transition to open-pit mining and is in negotiations with a contractor to finalize an agreement.

The company produced 230 gold equivalent ounces of doré during the commissioning phase, which began in December 2024, according to the release. It expects Casposo to produce 4,000 to 6,000 gold equivalent ounces during Q4.

In the other release, Austral provided an updated mineral reserve estimate for Casposo reporting proven and probable gold contained to be 80,000 ounces of gold and 3.28 million ounces of silver with average grades of 1.31 g/t gold and 58.52 g/t silver from 2.15 million metric tons of ore.

3. Resouro Strategic Metals (TSXV:RSM)

Weekly gain: 88.64 percent
Market cap: C$29.14 million
Share price: C$0.415

Resouro Strategic Metals is a polymetallic exploration and development company working to advance its mineral properties in Brazil.

Its Tiros rare earth metals and titanium project is located in Minas Gerais, Brazil, and comprises 28 mineral rights covering an area of 497 square kilometers.

According to a May 2025 technical report, the site hosts a measured and indicated resource of 1.4 billion metric tons of ore grading 12 percent titanium dioxide and 4,000 parts per million of total rare earth content.

The company also owns the Novo Mundo gold project located in the Alta Floresta gold province in Central Brazil. It consists of three licenses totaling 167 square kilometers.

On Tuesday, Resouro provided an update to its ongoing private placement, noting that it had received subscription agreements and expects to close in the next week.

4. Nio Strategic Metals (TSXV:NIO)

Weekly gain: 75 percent
Market cap: C$16.24 million
Share price: C$0.175

Nio Strategic Metals is an exploration company working to advance its assets in Québec, Canada.

Its primary focus has been on its Oka rare earth and critical minerals project. The property hosts a past-producing niobium mine and several nearby mineralized zones.

According to the project page, Oka’s total measured and indicated resource is 10.63 million metric tons of ore at an average grade of 0.65 percent niobium oxide.

While the company did not release any news this week, shares in Nio Strategic Metals rose significantly.

5. Boron One (TSXV:BONE)

Weekly gain: 71 percent
Market cap: C$14.92 million
Share price: C$0.06

Boron One is an exploration company focused on advancing its Piskanja project located near Belgrade, Serbia.

The asset hosts two primary densely mineralized zones with gently undulating borate beds. The company was initially granted its exploration license in 2010, with the exclusive right to apply for a mining license.

In a preliminary economic assessment for the project released in June 2022, Boron One, then named Erin Ventures, reported an economic case with an after-tax, net present value of US$524.9 million with an internal rate of return of 78.7 percent and a payback period of 12 months.

It also provided a mineral resource statement that demonstrated a measured and indicated resource of 2.36 million metric tons of boric oxide from 6.87 million metric tons of ore with an average grade of 34.36 percent boric oxide.

The most recent news from the project came on September 26 when the company provided an update on its application for a mining license, noting the Ministry of Mining has requested amendments to the company’s application before it can be approved.

Boron One said it is preparing the revised version “as quickly as possible.”

FAQs for Canadian mining stocks

What is the difference between the TSX and TSXV?

The TSX, or Toronto Stock Exchange, is used by senior companies with larger market caps, and the TSXV, or TSX Venture Exchange, is used by smaller-cap companies. Companies listed on the TSXV can graduate to the senior exchange.

How many mining companies are listed on the TSX and TSXV?

As of May 2025, there were 1,565 companies listed on the TSXV, 910 of which were mining companies. Comparatively, the TSX was home to 1,899 companies, with 181 of those being mining companies.

Together, the TSX and TSXV host around 40 percent of the world’s public mining companies.

How much does it cost to list on the TSXV?

There are a variety of different fees that companies must pay to list on the TSXV, and according to the exchange, they can vary based on the transaction’s nature and complexity. The listing fee alone will most likely cost between C$10,000 to C$70,000. Accounting and auditing fees could rack up between C$25,000 and C$100,000, while legal fees are expected to be over C$75,000 and an underwriters’ commission may hit up to 12 percent.

The exchange lists a handful of other fees and expenses companies can expect, including but not limited to security commission and transfer agency fees, investor relations costs and director and officer liability insurance.

These are all just for the initial listing, of course. There are ongoing expenses once companies are trading, such as sustaining fees and additional listing fees, plus the costs associated with filing regular reports.

How do you trade on the TSXV?

Investors can trade on the TSXV the way they would trade stocks on any exchange. This means they can use a stock broker or an individual investment account to buy and sell shares of TSXV-listed companies during the exchange’s trading hours.

Article by Dean Belder; FAQs by Lauren Kelly.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Lauren Kelly, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

President Trump is calling on House Republicans to vote to release files related to disgraced financier Jeffrey Epstein, insisting he has ‘nothing to hide’ and accusing Democrats of using the case as a distraction from GOP accomplishments.

In a Truth Social post on Sunday, Trump urged House Republicans to vote in favor of releasing the documents, describing the controversy as a ‘Democrat hoax perpetrated by radical left lunatics.’

‘As I said on Friday night aboard Air Force One to the Fake News Media, House Republicans should vote to release the Epstein files, because we have nothing to hide, and it’s time to move on from this Democrat Hoax perpetrated by Radical Left Lunatics in order to deflect from the Great Success of the Republican Party, including our recent Victory on the Democrat ‘Shutdown,” Trump wrote.

Trump pointed to the Department of Justice’s (DOJ) previous release of thousands of pages of Epstein-related documents. 

He also noted that the agency is investigating possible ties between Epstein and ‘Democrat operatives’ including former President Bill Clinton, LinkedIn co-founder Reid Hoffman and former Treasury Secretary Larry Summers.

‘The House Oversight Committee can have whatever they are legally entitled to, I DON’T CARE!’ Trump said.

He added, ‘All I do care about is that Republicans get BACK ON POINT, which is the Economy, ‘Affordability’ (where we are winning BIG!), our Victory on reducing Inflation from the highest level in History to practically nothing, bringing down prices for the American People, delivering Historic Tax Cuts, gaining Trillions of Dollars of Investment into America (A RECORD!), the rebuilding of our Military, securing our Border, deporting Criminal Illegal Aliens, ending Men in Women’s Sports, stopping Transgender for Everyone, and so much more!’

Trump also argued that if the Democrats ‘had anything,’ it would have surfaced prior to last year’s presidential election.

‘Nobody cared about Jeffrey Epstein when he was alive and, if the Democrats had anything, they would have released it before our Landslide Election Victory,’ Trump said. ‘Some ‘members’ of the Republican Party are being ‘used,’ and we can’t let that happen. Let’s start talking about the Republican Party’s Record Setting Achievements, and not fall into the Epstein ‘TRAP,’ which is actually a curse on the Democrats, not us. MAKE AMERICA GREAT AGAIN!’

Attorney General Pam Bondi announced Friday the DOJ would probe prominent Democrats after new emails revealed ties to Epstein.

In an X post Friday afternoon, Bondi said Jay Clayton, U.S. attorney for the Southern District of New York, would take the lead on the investigation.

‘Clayton is one of the most capable and trusted prosecutors in the country,’ Bondi wrote in the post. ‘As with all matters, the Department will pursue this with urgency and integrity to deliver answers to the American people.’

Fox News Digital has reached out to the White House, Bill Clinton, Reid Hoffman and Larry Summers for comment.

Fox News Digital’s Alexandra Koch contributed to this report.

This post appeared first on FOX NEWS

Vince Lanci of Echobay Partners explains what’s driving silver’s record-setting price run.

According to Lanci, who is also a professor at the University of Connecticut and publisher of the GoldFix newsletter on Substack, the London market is facing a liquidity crisis as nations that would typically sell or lend their silver choose to keep the metal at home.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Secretary of State Marco Rubio announced Sunday that the Cartel de los Soles, a powerful criminal network tied to Venezuela’s top leadership, will be labeled as a Foreign Terrorist Organization (FTO). 

The move appears to be an escalation in Washington’s stance toward the Venezuelan government and could lead to military action against the Maduro regime. 

In a statement, Rubio confirmed the U.S. will formally designate the cartel as an FTO later this month.

The designation, which is to take effect Nov. 24, targets the criminal network allegedly led by Venezuelan strongman Nicolás Maduro and senior members of his regime.

According to the State Department, ‘Based in Venezuela, the Cartel de los Soles is headed by Nicolás Maduro and other high-ranking individuals of the illegitimate Maduro regime who have corrupted Venezuela’s military, intelligence, legislature, and judiciary.’

‘Neither Maduro nor his cronies represent Venezuela’s legitimate government,’ the statement read.

‘The Cartel de los Soles, in coordination with other terrorist organizations including Tren de Aragua and the Sinaloa Cartel, is responsible for terrorist violence across our hemisphere and for trafficking drugs into the United States and Europe.’

The announced action is being taken under Section 219 of the Immigration and Nationality Act, which authorizes the State Department to designate foreign entities engaged in terrorist activity. 

The designation will become official once it’s published in the Federal Register.

The Cartel de los Soles had previously been sanctioned by the U.S. Treasury Department under Executive Order 13224, which targets terrorists and those providing support to terrorism.

In an accompanying post on X, Rubio said:

.@StateDept intends to designate Cartel de los Soles as a Foreign Terrorist Organization (FTO). Headed by the illegitimate Nicolás Maduro, the group has corrupted the institutions of government in Venezuela and is responsible for terrorist violence conducted by and with other designated FTOs as well as for trafficking drugs into the United States and Europe.

The statement came as President Trump reiterated that the U.S. was intent on stopping drug dealers and drugs filtering into the country.

‘We’re stopping drug dealers and drugs from coming into our country,’ Trump told reporters Sunday night.

‘And I actually told Marco and some of the people our secretary of state is doing a great job, by the way. I said, ‘Go to Congress and let them know we’re not letting drugs come through Mexico. We’re not letting them come through Venezuela,” he added.

Trump’s comments came just after he said that the government may be having discussions with Venezuela as well as confirming whether the new cartel designation would mean the U.S. government could now target Maduro’s assets or infrastructure.

It allows us to do that,’ Trump confirmed while mentioning talks with the Venezuelan leader.

‘We may be having some discussions with Maduro, and we’ll see how that turns out. They would like to talk,’ he said before adding, ‘We’ll see what happens.’

Fox News Digital has reached out to the Department of State for comment.

This post appeared first on FOX NEWS

From new stealth bombers to AI-enabled drones, the U.S. and China are reshaping airpower for a Pacific showdown – each betting its technology can keep the other out of the skies.

The U.S. is charging ahead with its next-generation F-47 fighter, while China scrambles to catch up with jets designed to match the F-35 and F-22.

After a brief program pause in 2024, the Air Force awarded Boeing the contract in March for the F-47, a manned sixth-generation fighter meant to anchor America’s next air superiority fleet. The first flight is expected in 2028.

At the same time, the B-21 Raider, the stealth successor to the B-2, is deep into testing at Edwards Air Force Base. The Air Force plans to buy at least 100 Raiders – each built to survive inside heavily defended Chinese airspace.

The Pentagon is also betting on Collaborative Combat Aircraft, or CCAs – drones designed to fly alongside fighters as ‘loyal wingmen.’ Prototypes from Anduril and General Atomics are already in the air. Officials say CCAs will let one pilot control several drones at once.

China outpaces the rest of the world in the commercial drone market, but that doesn’t necessarily give it the advantage from a military perspective. 

‘I’m not sure that’s really true. In terms of high-end military drones that are really important to this fight, the U.S. still has a pretty significant edge.’ said Eric Heginbotham, a research scientist at MIT’s Center for International Studies. 

He pointed to the Air Force’s stealth reconnaissance platforms – the RQ-170 and RQ-180 – and upcoming ‘loyal wingman’ drones designed to fly with fighters as proof that the U.S. still leads in advanced integration and stealth technology.

China’s leap forward

China’s airpower modernization has accelerated as the U.S. reshapes its force. Beijing has zeroed in on three priorities – stealth, engines and carriers – the areas that long held its military back.

The Chengdu J-20, China’s flagship stealth fighter, is being fitted with the new WS-15 engine, a home-built powerplant meant to rival U.S. engines.

‘It took them a while to get out of the blocks on fifth generation, especially to get performance anywhere near where U.S. fifth gen was,’ Heginbotham said. ‘The J-20 really does not have a lot of the performance features that even the F-22 does, and we’ve had the F-22 for a long time.’

Meanwhile, China’s third aircraft carrier, the Fujian, was commissioned this fall – the first with electromagnetic catapults similar to U.S. Ford-class carriers. The move signals Beijing’s ambition to launch stealth jets from sea and project power well beyond its coast.

Together, the J-20, the carrier-based J-35, and the Fujian give China a layered airpower network – stealth jets on land and at sea backed by growing missile coverage.

Chinese military writings identify airfields as critical vulnerabilities. PLA campaign manuals call for striking runways early in a conflict to paralyze enemy air operations before they can begin. Analysts believe a few days of concentrated missile fire could cripple U.S. bases across Japan, Okinawa and Guam.

‘The U.S. bases that are forward deployed – particularly on Okinawa, but also on the Japanese mainland and on Guam – are exposed to Chinese missile attack,’ said Mark Cancian, a retired Marine colonel and senior advisor at the Center for Strategic and International Studies. ‘In our war games, the Chinese would periodically sweep these air bases with missiles and destroy dozens, in some cases even hundreds, of U.S. aircraft.’

Heginbotham said that missile-heavy strategy grew directly out of China’s early airpower weakness.

‘They didn’t think that they could gain air superiority in a straight-up air-to-air fight,’ he said. ‘So you need another way to get missiles out – and that another way is by building a lot of ground launchers.’

Different strategies, same goal

The two militaries are taking different paths to the same target: air dominance over the Pacific.

The U.S. approach relies on smaller numbers of highly advanced aircraft linked by sensors and artificial intelligence. The goal: strike first, from long range, and survive in contested skies.

China’s model depends on volume – mass-producing fighters, missiles, and carrier sorties to overwhelm U.S. defenses and logistics.

‘U.S. fighter aircraft – F-35s, F-15s, F-22s – are relatively short-legged, so they have to get close to Taiwan if they’re going to be part of the fight,’ Cancian said. ‘They can’t fight from Guam, and they certainly can’t fight from further away. So if they’re going to fight, they have to be inside that Chinese defensive bubble.’

Both sides face the same challenge: surviving inside that bubble. China’s expanding missile range is pushing U.S. aircraft farther from the fight, while American bombers and drones are designed to break back in.

The fight to survive

Heginbotham said survivability – not dogfighting – will define the next decade of air competition.

‘We keep talking about aircraft as if it’s going to be like World War II – they go up, they fight each other. That’s not really our problem,’ he said. ‘Our problem is the air bases themselves and the fact that aircraft can be destroyed on the air base.’

China, he warned, is preparing for that reality while the U.S. is not.

‘They practice runway strikes in exercises, they’re modeling this stuff constantly,’ Heginbotham said. ‘Unlike the United States, China is hardening its air bases. The U.S. is criminally negligent in its refusal to harden its air bases.’

Cancian’s war-game findings echo that vulnerability. He said U.S. surface ships and aircraft would likely have to fall back under missile fire in the opening days of a conflict.

‘At the initial stages of a conflict, China would have a distinct advantage,’ Cancian said. ‘Now, over time, the U.S. would be able to reinforce its forces, and that would change.’

Looking ahead

The Pentagon’s fiscal 2026–27 budget will determine how fast the U.S. can build out its F-47s, B-21s and CCAs – systems that will shape American airpower through the 2030s.

China’s rapid modernization is closing what was once a wide gap, but the U.S. still holds advantages in stealth integration, combat experience and autonomous systems.

‘The ability to protect our aircraft, whatever form those aircraft take, on the ground is going to be central to our ability to fight in the Asia theater,’ Heginbotham said.

‘Survivability is going to be key… The ability to protect and disperse your firepower is going to be central to whether we can really stay in this game.’

For decades, U.S. air dominance was taken for granted. In the Pacific, that advantage is no longer guaranteed. 

This post appeared first on FOX NEWS

Don Durrett of GoldStockData.com outlines current gold and silver market dynamics, explaining why the metals continue to rise and how high they could go in the future.

He also shares his current gold and silver stock strategy.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com